港股通创新药ETF嘉实8月7日上市

Core Viewpoint - The launch of the Hong Kong Stock Connect Innovative Drug ETF by Harvest on August 7 has seen significant trading activity and premium, indicating strong investor interest in the innovative drug sector [1]. Group 1: Market Performance - The trading volume of the Hong Kong Stock Connect Innovative Drug ETF reached 166 million yuan on its first day, with a premium rate of 0.68% [1]. Group 2: Industry Analysis - Analysts suggest that the favorable fundamentals in the innovative drug sector, along with ongoing policy support, are driving investor interest in related assets [1]. - Dongwu Securities anticipates that with policy backing, the pharmaceutical industry is likely to achieve a win-win situation among medical services, insurance, and pharmaceuticals, enhancing the accessibility and affordability of innovative drugs and medical devices [1]. Group 3: Product Expansion - Harvest has been expanding its ETF offerings to help investors capture opportunities in the pharmaceutical sector, with the recent launch of the Hong Kong Stock Connect Innovative Drug ETF joining existing products like the Sci-Tech Pharmaceutical ETF and the Biopharmaceutical ETF [1].